

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL

{ } Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the

(Print or Type Responses) Investment Company Act of 1940

1. Name and Address of Reporting Person* Sanderling Venture Partners IV, L.P.	2. Issuer Name and Ticker or Trading Symbol CARDIONET INC BEAT	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner <input type="checkbox"/> Officer <input type="checkbox"/> Other
(Last) (First) (Middle) 400 SOUTH EL CAMINO REAL, SUITE 1200 (Street) SAN MATEO - CA - 94402 (City) (State) (Zip)	3. Date of Earliest Transaction (Month/Day/Year) 03-25-2008	(give title below) (specify below)
	4. If Amendment, Date Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) <input type="checkbox"/> Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

Table I -- Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2a. Deemed Execut. Date (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Sec Beneficially Owned Following Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03-25-2008		C	26,860 (A) #1	26,860	I	See Footnote #2
Common Stock	03-25-2008		C	5,640 (A) #3	32,501	I	See Footnote #2
Common Stock	03-25-2008		C	8,506 (A) #10 \$3.5	41,007	I	See Footnote #2
Common Stock	03-25-2008		C	11,370 (A) #4	52,377	I	See Footnote #2
Common Stock	03-25-2008		C	111,919 (A) #1	111,919	I	See Footnote #5
Common Stock	03-25-2008		C	23,503 (A) #3	135,422	I	See Footnote #5
Common Stock	03-25-2008		C	35,449 (A) #10 \$3.5	170,871	I	See Footnote #5

Common Stock	03-25-2008		C		47,287	A		218,158	I	See Footnote #5
Common Stock	03-25-2008		C		30,187	A	#1	30,187	I	See Footnote #6
Common Stock	03-25-2008		C		6,339	A	#3	36,526	I	See Footnote #6
Common Stock	03-25-2008		C		9,560	A	\$3.5 #10	46,086	I	See Footnote #6
Common Stock	03-25-2008		C		12,774	A	#4	58,860	I	See Footnote #6
Common Stock	03-25-2008		C		184,604	A	#1	184,604	I	See Footnote #7
Common Stock	03-25-2008		C		38,767	A	#3	223,371	I	See Footnote #7
Common Stock	03-25-2008		C		58,472	A	\$3.5 #10	281,843	I	See Footnote #7
Common Stock	03-25-2008		C		77,920	A	#4	359,763	I	See Footnote #7

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1.	2.	3.	3a.	4.	5.	6.	7.	8.	9.	10.	11.
Title of Derivative Security (Instr. 3)	Conversion or Exercise Price of Derivative Security	Transaction Date (Month/Day/Year)	Deemed Executed Date (Month/Day/Year)	Transaction Code (Instr. 8)	Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	Date Exercisable and Expiration Date (Month/Day/Year)	Title and Amount of Underlying Securities (Instr. 3 and 4)	Price of Derivative Security (Instr. 5)	Number of Derivative Securities Owned Following Reported Transaction (Instr. 4)	Ownership Form of Derivative Security (D) or Indirect (I)	Nature of Indirect Beneficial Ownership (Instr. 4)
Series C Convertible Preferred Stock	#1	03-25-2008		C	53,721		Common Stock	\$0	0	I	See Footnote #2
Series D Convertible Preferred Stock	#1	03-25-2008		C	11,281		Common Stock	\$0	0	I	See Footnote #2

	#3					#3	#3							#2
Warrants to Purchase Series D-1 Convertible Preferred Stock	\$3.58	03-25-2008	C			27,844		Common Stock	8,506	\$0	0		I	See Footnote
						#8	#9	#10						#2
Mandatory Convertible Preferred Stock		03-25-2008	C			170		Common Stock	11,370	\$0	0		I	See Footnote
	#4					#4	#4							#2
Series C Convertible Preferred Stock		03-25-2008	C			223,839		Common Stock	111,919	\$0	0		I	See Footnote
	#1					#1	#1							#5
Series D Convertible Preferred Stock		03-25-2008	C			47,006		Common Stock	23,503	\$0	0		I	See Footnote
	#3					#3	#3							#5
Warrants to Purchase Series D-1 Convertible Preferred Stock	\$3.58	03-25-2008	C			116,019		Common Stock	35,449	\$0	0		I	See Footnote
						#8	#9	#10						#5
Mandatory Convertible Preferred Stock		03-25-2008	C			707		Common Stock	47,287	\$0	0		I	See Footnote
	#4					#4	#4							#5
Series C Convertible Preferred Stock		03-25-2008	C			60,374		Common Stock	30,187	\$0	0		I	See Footnote
	#1					#1	#1							#6
Series D Convertible Preferred Stock		03-25-2008	C			12,679		Common Stock	6,339	\$0	0		I	See Footnote
	#3					#3	#3							#6
Warrants to Purchase Series D-1 Convertible Preferred Stock	\$3.58	03-25-2008	C			31,293		Common Stock	9,560	\$0	0		I	See Footnote



SAN MATEO CA 94402				
Sanderling Venture Partners V Co Investment Fund, LP 400 SOUTH EL CAMINO REAL SUITE 1200 SAN MATEO CA 94402	.	X		
SANDERLING V LTD PARTNERSHIP 400 SOUTH EL CAMINO REAL SUITE 1200 SAN MATEO CA 94402	.	X		

Explanation of Responses:

- 1 Each 2 shares of Series C Convertible Preferred Stock converted into 1 share of the Issuer's common stock upon the closing of the initial public offering for no additional consideration and had no expiration date.
- 2 By Sanderling V Beteiligungs GmbH & Co KG. Fred Middleton, a member of the Issuer's board of directors is a managing director of Middleton, McNeil & Mills Associates V, LLC the sole general partner of Sanderling V Beteiligungs GmbH & Co KG and has voting and investment power over the shares held by Sanderling V Beteiligungs GmbH & Co KG. Mr. Middleton disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
- 3 Each 2 shares of Series D Convertible Preferred Stock converted into 1 share of the Issuer's common stock upon the closing of the initial public offering for no additional consideration and had no expiration date.
- 4 Each share of Mandatorily Convertible Preferred Stock converted into 66.88 share of the Issuer's common stock upon the closing of the initial public offering for no additional consideration and had no expiration date.
- 5 By Sanderling V Biomedical Co-Investment Fund L.P. Fred Middleton, a member of the Issuer's board of directors is a managing director of Middleton, McNeil & Mills Associates V, LLC the sole general partner of Sanderling V Biomedical Co-Investment Fund L.P and has voting and investment power over the shares held by Sanderling V Biomedical Co-Investment Fund L.P. Mr. Middleton disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
- 6 By Sanderling V Limited Partnership. Fred Middleton, a member of the Issuer's board of directors is a managing director of Middleton, McNeil & Mills Associates V, LLC the sole general partner of Sanderling V Limited Partnership and has voting and investment power over the shares held by Sanderling V Limited Partnership. Mr. Middleton disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
- 7 By Sanderling Venture Partners V Co-Investment Fund, L.P. Fred Middleton, a member of the Issuer's board of directors is a managing director of Middleton, McNeil & Mills Associates V, LLC the sole general partner of Sanderling Venture Partners V Co-Investment Fund, L.P and has voting and investment power over the shares held by Sanderling Venture Partners V Co-Investment Fund, L.P. Mr. Middleton disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
- 8 Warrants became exercisable on March 8, 2007.
- 9 Warrants to purchase Series D-1 Convertible Preferred were automatically net exercised immediately prior to the closing of the Issuer's initial public offering. Each 2 shares of Series D-1 Convertible Preferred Stock converted into 1 share of the Issuer's common stock upon the closing of the initial public offering for no additional consideration and had no expiration date.
- 10 Warrants were net exercised resulting in fewer shares being issued than if the exercise price had been paid for with cash.

Remarks:

Exhibit 24.1 Power of Attorney

Signatures

See Ex. 99.1

/ 03-26-2008

---  
\*\* Signature of Reporting Person

---  
Date

\* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations.  
See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form

Exhibit 24.1

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints each of Martin P. Galvan and Doreen Roberts, signing individually, the undersigned's true and lawful attorneys-in fact and agents to:

(1) execute for and on behalf of the undersigned, an officer, director or holder of 10% or more of a registered class of securities of CardioNet, Inc. (the "Company"), Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and the rules thereunder;

(2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute such Form 3, 4 or 5, complete and execute any amendment or amendments thereto, and timely file such forms or amendments with the United States Securities and Exchange Commission and any stock exchange or similar authority; and

(3) take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact or (c) as to any attorney-in-fact individually, until such attorney-in-fact shall no longer be employed by the Company.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 17th day of March, 2008.

-----  
SANDERLING VENTURE PARTNERS IV, L.P.  
By: Middleton-McNeil Associates IV, L.P.  
By: /s/ Fred A. Middleton  
Fred A. Middleton  
General Partner

SANDERLING IV BIOMEDICAL, L.P.  
By: Middleton-McNeil Associates IV, LLC  
By: /s/ Fred A. Middleton  
Fred A. Middleton  
General Partner

SANDERLING IV LIMITED PARTNERSHIP  
By: Middleton-McNeil Associates IV, L.P.  
By: /s/ Fred A. Middleton  
Fred A. Middleton  
General Partner

Sanderling {Feri Trust} Venture Partners IV  
By: Middleton-McNeil Investment Partners IV,  
L.P.  
By: /s/ Fred A. Middleton  
Fred A. Middleton  
General Partner

Sanderling Ventures Management IV  
By: /s/ Fred A. Middleton  
Fred A. Middleton  
Owner

SANDERLING VENTURE PARTNERS IV CO-INVESTMENT  
FUND, L.P.  
By: Middleton-McNeil Associates IV, LLC  
By: /s/ Fred A. Middleton  
Fred A. Middleton  
General Partner

SANDERLING IV BIOMEDICAL CO-INVESTMENT FUND,  
L.P.  
By: Middleton-McNeil Associates IV, LLC  
By: /s/ Fred A. Middleton  
Fred A. Middleton  
General Partner

-----  
SANDERLING VENTURE PARTNERS V CO-INVESTMENT FUND,

L.P.  
By: Middleton, McNeil & Mills Associates V, LLC  
By: /s/ Fred A. Middleton  
Fred A. Middleton  
Managing Director

SANDERLING V BIOMEDICAL CO-INVESTMENT FUND, L.P.  
By: Middleton, McNeil & Mills Associates V, LLC  
By: /s/ Fred A. Middleton  
Fred A. Middleton  
Managing Director

SANDERLING V LIMITED PARTNERSHIP  
By: Middleton, McNeil & Mills Associates V, LLC  
By: /s/ Fred A. Middleton  
Fred A. Middleton  
Managing Director

SANDERLING V BETEILIGUNGS GMBH & CO. KG  
By: Middleton, McNeil & Mills Associates V, LLC  
By: /s/ Fred A. Middleton  
Fred A. Middleton  
Managing Director

Sanderling Ventures Management V  
By: /s/ Fred A. Middleton  
Fred A. Middleton  
Owner

SANDERLING VENTURE PARTNERS VI CO-INVESTMENT FUND,  
L.P.  
By: Middleton, McNeil, Mills & Associates VI, LLC  
By: /s/ Fred A. Middleton  
Fred A. Middleton  
Managing Director

-----  
SANDERLING VI LIMITED PARTNERSHIP  
By: Middleton, McNeil, Mills & Associates  
VI, LLC  
By: /s/ Fred A. Middleton  
Fred A. Middleton  
Managing Director

SANDERLING VI BETEILIGUNGS GMBH & CO. KG  
By: Middleton, McNeil, Mills & Associates  
VI, LLC  
By: /s/ Fred A. Middleton  
Fred A. Middleton  
Managing Director

Sanderling Ventures Management VI  
By: /s/ Fred A. Middleton  
Fred A. Middleton  
Owner

Exhibit 99.1

SANDERLING VENTURE PARTNERS IV, L.P.

By: Middleton-McNeil Associates IV,  
L.P.

By: Fred A. Middleton  
General Partner  
By: /s/ Doreen Roberts  
Name: Doreen Roberts  
Title: Atty-in-Fact for  
Fred A. Middleton

SANDERLING V BETEILIGUNGS GMBH & CO.  
KG

By: Middleton, McNeil & Mills  
Associates V, LLC

By: Fred A. Middleton  
Managing Director  
By: /s/ Doreen Roberts  
Name: Doreen Roberts  
Title: Atty-in-Fact for  
Fred A. Middleton

SANDERLING V BIOMEDICAL CO-INVESTMENT FUND, L.P.

By: Middleton, McNeil & Mills  
Associates V, LLC

By: Fred A. Middleton  
Managing Director  
By: /s/ Doreen Roberts  
Name: Doreen Roberts  
Title: Atty-in-Fact for  
Fred A. Middleton

SANDERLING VENTURE PARTNERS V  
CO-INVESTMENT FUND, L.P.

By: Middleton, McNeil & Mills Associates  
V, LLC

By: Fred A. Middleton  
Managing Director  
By: /s/ Doreen Roberts  
Name: Doreen Roberts  
Title: Atty-in-Fact for  
Fred A. Middleton

SANDERLING V LIMITED PARTNERSHIP

By: Middleton, McNeil & Mills Associates  
V, LLC

By: Fred A. Middleton  
Managing Director  
By: /s/ Doreen Roberts  
Name: Doreen Roberts  
Title: Atty-in-Fact for  
Fred A. Middleton